Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05799833
Other study ID # 22IC7985
Secondary ID WHCC_PA2965
Status Recruiting
Phase
First received
Last updated
Start date October 9, 2023
Est. completion date November 1, 2025

Study information

Verified date October 2023
Source Imperial College London
Contact Sabiha Gati, MBBS
Phone 07977 352296
Email s.gati@rbht.nhs.uk
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

There is some limited evidence that reduced size of electrical complexes/traces of the heart on the electrocardiogram (ECG) may be associated with scarring in the heart muscle, which may predispose to serious life-threatening electrical abnormalities and sudden cardiac death (SCD). There is no current guidance on how young individuals and athletes with reduced ECG traces should be managed. Therefore, correct interpretation of this ECG finding is crucial for identifying athletes with disease and at risk of SCD. Some athletes experience SCD despite normal standard cardiac tests. The investigators, therefore, propose to study young healthy individuals and young athletes using cardiovascular MRI, cardiopulmonary exercise testing, 24 hour ECG monitoring and genetic analysis to determine the significance of reduced ECG traces and possibly revise current international sports recommendations.


Description:

There is emerging evidence that low QRS voltages <0.5mV in the limb leads may be associated with left ventricular myocardial fibrosis and a predisposition to serious ventricular arrhythmias and sudden cardiac death (SCD). Sudden death in young individuals is highlighted most commonly when an athlete is affected. A proportion of decedents are diagnosed with idiopathic myocardial fibrosis at autopsy. Recent studies have revealed myocardial fibrosis in athletes with low QRS complexes, who have survived a sudden cardiac arrest. Low QRS voltages do not feature in the electrical anomalies that warrant further investigation according to the international recommendations for electrocardiographic (ECG) interpretation in athletes, hence there is no information on the precise significance or outcome data in athletes with small QRS voltages. The investigators postulate that further evaluation of athletes with low QRS voltages using CMR and gene analysis will help determine the prevalence and significance of these ECG changes potentially identifying young vulnerable individuals at risk of SCD. There are currently 2 studies which have assessed small QRS complexes in athletes. These studies revealed 1.1-4% of Italian athletes had small QRS complexes. One study performed ultrasound of the heart showing that athletes in general had larger hearts compared to sedentary counterparts but no evidence of structural disease. The second study did not perform CMR in all athletes with small QRS complexes and only conducted CMR in 5 athletes with small QRS complexes and electrical issues and demonstrated scar in 2 athletes. The scientific basis of these studies does not prove the precise significance of small QRS complexes on the ECG in this population to elucidate the sensitivity and specificity of disease identification. It is possible that young individuals with serious cardiac abnormalities may be identified if the significance of small QRS complexes is elucidated. The prevalence of small QRS complexes in the general population is 0.3-2% but there is paucity of data on prevalence and significance on small QRS complexes in young non-athletic individuals aged 17-35 years old. This study will allow the investigators to identify the prevalence and significance of small QRS complexes in athletes and non-athletes aged 17-35 years old potentially identifying young vulnerable individuals at risk of sudden cardiac death. These results should enable informed clinical decisions (at national and international level) following pre-participation screening evaluation and help ultimately to identify young individuals and athletes who are genuinely deemed to be at risk of sudden cardiac death (SCD) whilst providing appropriate reassurance to those with normal QRS voltages. This study will also potentially aid the investigators in updating the current recommendations on ECG interpretation in athletes which will influence future international ECG recommendations in athletes.This would be a cross-sectional observational study involving 240 participants aged 17-35 years old. This will involve 4 groups; 60 athletes with low QRS voltage and 60 age and sex matched control group of athletes with normal QRS voltage, 60 non-athletes with low QRS voltage and 60 age and sex matched controls with normal QRS voltage.


Recruitment information / eligibility

Status Recruiting
Enrollment 240
Est. completion date November 1, 2025
Est. primary completion date May 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 17 Years to 35 Years
Eligibility Inclusion Criteria: - No cardiovascular symptoms - Body mass index <30. Exclusion Criteria: - Individuals with cardiac symptoms; - Past medical history of cardiac disease, previous myocarditis or lung disease; - Individuals with pacemakers or defibrillators - Family history of SCD <40 years old or cardiomyopathy - Pregnant women - Advanced kidney and/or liver disease - Known thyroid disease, - T-wave inversion or other training unrelated ECG changes - Known significant valvular heart disease or intra-cardiac shunt on echocardiography.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Cardiovascular magnetic resonance scan - 3T scanner (Siemens Vida)
4 study groups will undergo testing with 12-lead ECG, blood test, cardiac MRI, cardiopulmonary exercise testing and 24 hour holter monitor. A subgroup (N=50 anticipated) will undergo genetic testing.

Locations

Country Name City State
United Kingdom Royal Brompton Hospital London

Sponsors (4)

Lead Sponsor Collaborator
Imperial College London Cardiac Risk in the Young, Royal Brompton & Harefield NHS Foundation Trust, St George's, University of London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of low QRS voltages in athletes and young non-athletic population on ECG analysis Prevalence data will be obtained from existing ECG database of athletes and young people who have been screened by Cardiac risk in the young. 36 months
Primary Prevalence of myocardial fibrosis in the young athletic and non-athletic population with low QRS Participants satisfying inclusion criteria will undergo a cardiac MRI at a single time point to identify those with late gadolinium enhancement (indication of myocardial fibrosis) 36 months
Secondary The proportion of individuals with low QRS complexes and myocardial fibrosis with rare protein altering variant in a cardiomyopathy gene. A subgroup of athletes and young health individuals with low QRS voltages and myocardial fibrosis on cardiac MRI will undergo genetic analysis to identify the presence of protein altering genetic variants in known cardiomyopathy causing genes 36 months
Secondary The proportion of individuals with low QRS complexes and myocardial fibrosis with exercise related ventricular premature beats or a ventricular premature beat burden of > 500 beats on a Holter monitor All participants will undergo cardiopulmonary exercise tests and 24 hour holter monitoring to identify presence of exercise related ventricular premature beats and a ventricular premature beat burden of > 500 beats on a Holter monitor 36 months
See also
  Status Clinical Trial Phase
Completed NCT02923726 - Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP N/A
Recruiting NCT05175937 - REal World Assessment for Patients Implanted With Implantable CardioverTer DefibrIllatOr Using Bluetooth Technology
Completed NCT02026102 - A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs) N/A
Completed NCT01262508 - Development of Algorithms to Predict Hemodynamic Instability N/A
Completed NCT00998218 - Effect of Ranolazine on Arrhythmias and Microvolt T- Wave Alternans (MVTWA) Patients With LV Dysfunction Phase 3
Completed NCT00845286 - Marathon, Genetics, Inflammation and the Cardiovascular System: MAGIC-Trial N/A
Active, not recruiting NCT00562757 - Prospective Study to Identify Patients at Risk of Dangerous Ventricular Arrhythmias N/A
Completed NCT00622453 - Arrhythmias in Myotonic Muscular Dystrophy N/A
Completed NCT03833843 - Sudden Cardiac Death in Systemic Right Ventricle
Completed NCT04024865 - Domperidone and Risk of Serious Cardiac Events in Postpartum Women
Recruiting NCT05694572 - Post-market Surveillance of Micorport CRM Cardiac Implantable Electronic Devices
Not yet recruiting NCT03622307 - Subcutaneous ICD Therapy Combined With VT Ablation for the Secondary Prevention of Sudden Cardiac Death N/A
Recruiting NCT02056509 - The Effect of Chest Compression and Ventilation Coordination During Cardiopulmonary Resuscitation. N/A
Recruiting NCT02058771 - Utilising Lifemap to Investigate Malignant Arrhythmia Therapy
Terminated NCT01948206 - Study of Paced QRS Duration as a Marker of Sudden Cardiac Death N/A
Completed NCT01227785 - Next Generation INCEPTA Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy (CRT-D) Field Following Study N/A
Completed NCT00534300 - Intravenous n-3 Fatty Acids and Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillator (ICD)-Pacemaker Phase 1/Phase 2
Terminated NCT00524862 - Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death N/A
Recruiting NCT00181233 - Imaging Techniques for Identifying Factors of Sudden Cardiac Death Risk
Active, not recruiting NCT04036695 - Arrhythmia in Hemodialysis Patients N/A